Trials / Enrolling By Invitation
Enrolling By InvitationNCT04220671
Measles Vaccination at Health System Contacts
Health Effects of Utilising Curative Health System Contacts to Provide Measles Vaccination - a Randomised Controlled Trial
- Status
- Enrolling By Invitation
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 5,400 (estimated)
- Sponsor
- Bandim Health Project · Academic / Other
- Sex
- All
- Age
- 9 Months – 59 Months
- Healthy volunteers
- Not accepted
Summary
In addition to protecting against measles infection, measles vaccine (MV) strengthens the individual's ability to combat infections in general - MV has beneficial non-specific effects (NSE) lowering the risk of death and admissions by around 30%. In Guinea-Bissau 30% of children do not receive a routine MV scheduled at 9 months of age, putting both the individual child's health and measles eradication at risk. The coverage of a second dose of MV, which was added to the Bissau-Guinean vaccination programme in 2022, is even lower. WHO recommends vaccination at health system contacts, including those for curative services. At the paediatric ward of the national hospital in Guinea-Bissau, there are more than 2600 yearly contacts with measles-un or under-vaccinated children aged 9-59 months, but no vaccines are given. In a randomised controlled trial, we will assess the effect of providing MV vs placebo to 5400 children at hospital contacts (at discharge or after an out-patient consultation) to test the hypothesis that MV reduces the risk of admission or death (composite outcome) by 25% over the subsequent 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | measles vaccine | Measles vaccine, Edmonston-Zagreb strain, 0.5 ml administered as a subcutaneous injection |
| OTHER | Saline | 0.9% NaCl |
Timeline
- Start date
- 2020-01-08
- Primary completion
- 2026-12-01
- Completion
- 2027-06-01
- First posted
- 2020-01-07
- Last updated
- 2025-07-29
Locations
1 site across 1 country: Guinea-Bissau
Source: ClinicalTrials.gov record NCT04220671. Inclusion in this directory is not an endorsement.